Lung Transplantation for Pulmonary Langerhans' Cell Histiocytosis: A Multicenter Analysis

Abstract

Severe pulmonary hypertension is a common feature in patients with end-stage PLCH. Given the good postransplant survival rate and despite a recurrence rate of the disease of approximately 20% after LT, we conclude that LT is a therapeutic option in this setting.